Biocon Biologics is set to integrate a major portion of the biosimilars business acquired from Viatris in the current fiscal year, according to Kiran Mazumdar-Shaw, Executive Chairperson of Biocon. The integration of the biosimilars business has already been completed in over 70 countries in emerging markets, and the company is now focusing on integrating it in the remaining markets, including North America and Europe.
